Background

HMA are standard of care in pts with high-risk MDS and commonly used in pts with lower risk. Pts with high-risk disease post HMA failure have a poor prognosis with a median survival of 4-6 months. The prognosis of pts with low and intermediate-1 risk MDS by the International Prognostic Scoring System (IPSS) after HMA failure is not known.

Aims

To assess outcome of pts with low and intermediate-1 risk disease post HMA failure that might benefit from specific strategies or investigational agents.

Methods

Data from 423 pts with low (n= 141, 33%) and intermediate-1 risk disease (n=282, 67%) by IPSS score treated with HMA at MD Anderson Cancer Center (MDACC; n=144) and Moffitt Cancer Center (MCC; n=279) between 2000 and 2011 were analyzed.

Results

Median age was 69 years. 294 (69%) pts had a diploid cytogenetic analysis. 63 (15%) pts had therapy-related MDS. 282 (67%) pts received azacitidine, 87 (21%) decitabine, and 54 (12%) both. Median number of cycles of HMA administered was 6 (range, 1-64) for a median duration of therapy of 7 months (range, 1- 74). Best response to HMA was complete response (CR) in 39 (9%) pts, partial response (PR) in 13 (3%), a bone marrow CR in 6 (1%), and hematologic improvement (HI) in 90 (21%) pts. Pts had discontinued HMA because of primary resistance in 198 (47%) pts, loss of response in 141 pts (33%), intolerance in 13 pts (3%) and other reasons in 71 pts (17%). At the time of HMA failure, 81 (19%) pts transformed into acute myeloid leukemia (AML). Of the 302 remaining pts evaluable by IPSS, 67 (22%) pts were of low-risk, 158 (53%) of intermediate-1 risk, 48 (16%) of intermediate-2 risk, and 29 (9%) of high-risk disease. By the revised IPSS (R-IPSS), the percentage of pts with low, very low, intermediate, high, and very high risk disease were 11%, 29%, 30%, 20%, and 10%, respectively. By the MDACC global prognostic scoring system (MDGPSS) 18%, 35%, 29%, and 18%, of the pts were of low-risk, intermediate-1, intermediate-2, and high-risk disease, respectively. After a median follow-up of 16 months from HMA failure, 117 (28%) pts remained alive. The median overall survival (OS) was 15 months (95% CI: 12-18) with estimated 1- and 3-year OS rates of 55% and 27%, respectively. Both, the R-IPSS and the MDGPSS were predictive of survival post HMA failure (Table 1 

Table 1

Survival from HMA failure by risk group

 Survival
Risk groupCategoryPercentageMedian (mos)% 1-year% 3-yearp-value
MDGPSS Low 18 34 68 48 p<0.001 
  Intermediate-1 35 29 75 39 
  Intermediate-2 29 12 49 14 
  High 18 7 31 8 
R-IPSS Very low 11 51 83 60 p<0.001 
  Low 29 31 76 38 
  Intermediate 30 21 60 30 
  High 20 9 39 12 
  Very high 10 6 25 11 
 Survival
Risk groupCategoryPercentageMedian (mos)% 1-year% 3-yearp-value
MDGPSS Low 18 34 68 48 p<0.001 
  Intermediate-1 35 29 75 39 
  Intermediate-2 29 12 49 14 
  High 18 7 31 8 
R-IPSS Very low 11 51 83 60 p<0.001 
  Low 29 31 76 38 
  Intermediate 30 21 60 30 
  High 20 9 39 12 
  Very high 10 6 25 11 
View Large

).

Conclusion

In the largest cohort of lower risk MDS pts treated with HMA, the outcome after HMA failure is poor. Treatment of those patients remains an unmet medical need. OS is a reasonable primary endpoint for clinical studies targeting this population.

Disclosures:

Lancet:Celgene: Research Funding. Sekeres:Celgene: Consultancy; Amgen: Consultancy. List:Celgene: Research Funding. Komrokji:Celgene: Research Funding, Speakers Bureau.

Topics:
brachial plexus neuritis, myelodysplastic syndrome, prostatic hypertrophy risk score, risk reduction, azacitidine, complete remission, cytogenetic analysis, decitabine, duration of treatment, follow-up

Author notes

*

Asterisk with author names denotes non-ASH members.

This icon denotes a clinically relevant abstract

© 2013 by The American Society of Hematology
2013
Sign in via your Institution